A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation

Trial Details

NCT ID
NCT07206498
Phase
PHASE1 / PHASE2
Sponsor
Wayshine Biopharm, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Osimertinib (Tagrisso®)
  • WSD0922-FU
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • ≥Age 18, gender is not limited;
  • Locally advanced or metastatic NSCLC confirmed by pathology;
  • Patients who have been genetically tested to carry EGFR sensitive mutations;
  • Blood/Tissue samples must be provided for testing;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →